Intriguingly, in 2007 Wan and coworkers demonstrated that rosiglitazone enhances RANKL-induced osteoclastogenesis in an PPARγ-dependent manner, proposing a concept that TZDs induce bone loss in patients with T2DM in part by promoting osteoclastogenesis [31]. Here, TNFSF11 is linked to type 2 diabetes mellitus.